In DLBCL, Brandt et al. [72] evaluated the expression of fibronectin (Fn1), another “stromal-1 gene,” and SPARC and concluded that combined immunohistochemical assessment of both of them is an important predictor of survival. This evidence concerns the gene FN1 and diffuse large B-cell lymphoma.